


of your kidney transplant patients are experiencing "silent" rejection.

Do you know which ones?

- 1** 25% of kidney transplant recipients experience "silent" subclinical acute rejection (subAR).
- 2** Untreated subAR leads to worse long-term outcomes.
- 3** TruGraf: the non-invasive blood test to rule out subAR.

- ✓ TruGraf detects an early change in gene expression as the immune system activates.
- ✓ TruGraf is reimbursable by Medicare for serially monitoring patients to detect "silent" subclinical acute rejection.
- ✓ TruGraf can be collected at the same time as routine bloodwork prior to the patient's next appointment.




Untreated subAR can lead to:



Higher risk for forming *de novo* donor-specific antibodies (DSA).



Higher risk of developing **clinical acute rejection**.



Higher risk of developing **graft fibrosis**.





More rapid **loss of kidney function**, i.e. glomerular filtration rate.




Higher risk of **graft loss at 5 years**.

Ref: DOI:10.1111/ajt.15011

		Donor-Derived Cell-Free DNA Tests
Patient Population	Stable renal function	Renal dysfunction
Rejection Type	“Silent” subclinical acute rejection including borderline	Clinical acute rejection
Context of Use	Upstream, pre-injury	Downstream, post-injury
Interpretation of Results	Dichotomous / Binary result: Positive (Not-TX) or Negative (TX)	Thresholds (e.g. 1%) used for performance validation; may need to calculate % change from prior values.

 Transplant eXcellence (**TX**), and adequately immunosuppressed.

 **Not-TX**, and may not be adequately immunosuppressed.

Simple to Interpret; Simple to Act

A **TX** result indicates that the patient is adequately immunosuppressed, and that “silent” subAR is unlikely. Therefore, a TX result indicates that the patient does not need a biopsy right now.

“If TX, skip the Bx”

A **Not-TX** result suggests that the patient may not be adequately immunosuppressed, and that additional monitoring may be necessary to determine rejection activity. (E.g., a Not-TX result may be followed by repeat TruGraf testing within 2-4 weeks; dd-cfDNA testing, DSA testing, a biopsy, or a referral to the transplant center for specialized care.)

TruGraf Offers Significant Patient Benefits:

- TruGraf offers patients and their caregivers confidence that they aren’t harboring “silent” subclinical acute rejection
- TruGraf is non-invasive, sparing patients the pain and recovery of more invasive tests.
- TruGraf is a convenient routine blood draw, performed in a hospital, clinic, commercial lab, or at home via Labs@HOME.

[Learn more at trugraf.com/kidney](https://trugraf.com/kidney)

Marketed By :



Duraent Lifesciences LLP

32/2, Soundararajan Street, T.Nagar,
Chennai - 600 017, India Tel: +91 44 42323244
Website: www.duraent.com
Email : ea@duraent.in Phone: +91 93455 93375